NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI) Financial Analysis & Valuation | Quarter Chart
NEONC TECHNOLOGIES HOLDINGS, INC. (NTHI)
NTHIPrice: $5.44
Fair Value: 🔒
🔒score
Neonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a ... more
Neonc Technologies Holdings, Inc. develops novel molecular technology that provides enhanced targete... more
Description
Shares
| Market Cap | $108.77M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Amir Farrokh Heshmatpour |
| IPO Date | 2025-03-26 | CAGR | — |
| Employees | 8 | Website | www.neonctech.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
NTHI chart loading...
Fundamentals
Technicals
| Enterprise Value | $107.03M | P/E Ratio | -1.7 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | 2.28 | P/B Ratio | -0.01 |
| P/CF Ratio | -0.01 | P/FCF Ratio | -0.01 |
| EPS | $-3.2 | EPS Growth 1Y | 259.22% |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | -4.78% | Gross Margin | 1% |
| Operating Margin | -872.37% | Profit Margin | -909.34% |
| ROE | 5.63% | ROA | -13.36% |
| ROCE | 4.55% | Current Ratio | 0.19 |
| Quick Ratio | 0.19 | Cash Ratio | 0.1 |
| Debt/Equity | -0.03 | Interest Coverage | 5659.48 |
| Altman Z Score | -75.44 | Piotroski Score | 3 |